LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Gilead Sciences Inc.

Closed

SectorHealthcare

112.97 0.41

Overview

Share price change

24h

Current

Min

112.5

Max

113.03

Key metrics

By Trading Economics

Income

645M

2B

Sales

414M

7.1B

P/E

Sector Avg

22.649

35.724

Dividend yield

2.72

Profit margin

27.68

Employees

17,600

EBITDA

769M

3.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+11.11% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.72%

3.09%

Next Dividend date

29 Sept 2025

Next Ex Dividend date

15 Sept 2025

Market Stats

By TradingEconomics

Market Cap

-804M

142B

Previous open

112.56

Previous close

112.97

News Sentiment

By Acuity

24%

76%

44 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Gilead Sciences Inc. Chart

Past performance is not a reliable indicator of future results.

Related News

21 Aug 2025, 13:45 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Interius BioTherapeutics for $350 Million

7 Aug 2025, 20:59 UTC

Earnings

Gilead Sciences Upgrades Guidance After 2Q Results Top Views

24 Apr 2025, 20:17 UTC

Earnings

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

21 Aug 2025, 12:35 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences Sees Transaction With Interius Cutting 2025 Adjusted EPS by 23c-25c >GILD

21 Aug 2025, 12:31 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Interius is Private Biotechnology Company Developing In-Vivo CAR Therapeutics >GILD

21 Aug 2025, 12:31 UTC

Acquisitions, Mergers, Takeovers

Gilead's Kite to Buy Interius BioTherapeutics for $350 Million >GILD

21 Aug 2025, 12:30 UTC

Acquisitions, Mergers, Takeovers

Kite To Acquire Interius BioTherapeutics To Advance In Vivo Platform >GILD

8 Aug 2025, 20:28 UTC

Earnings

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 Aug 2025, 17:27 UTC

Earnings

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 Aug 2025, 12:03 UTC

Earnings

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

8 Aug 2025, 11:13 UTC

Earnings

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

7 Aug 2025, 21:13 UTC

Earnings

Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot -- Barrons.com

7 Aug 2025, 20:44 UTC

Earnings

Gilead Sciences Ups Guidance After 2Q Results Top Views

7 Aug 2025, 20:26 UTC

Earnings

Gilead Sciences: Liver Disease Portfolio Sales Decreased 4% to $795M in 2Q >GILD

7 Aug 2025, 20:26 UTC

Earnings

Gilead Sciences: 2Q Descovy Sales Increased 35% to $653M >GILD

7 Aug 2025, 20:25 UTC

Earnings

Gilead Sciences: HIV Pdt Sales Increased 7% to $5.1 B in 2Q >GILD

7 Aug 2025, 20:24 UTC

Earnings

Gilead Sciences: 2Q Biktarvy Sales Increased 9% Yr-Over-Yr to $3.5 B >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences 2Q Adj EPS $2.01 >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences 2Q Net $1.96B >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences Sees FY EPS $5.85-EPS $6.15 >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences 2Q Rev $7.1B >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences 2Q Total Liver Disease Sales $211M >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences Sees FY Adj EPS $7.95-Adj EPS $8.25 >GILD

7 Aug 2025, 20:22 UTC

Earnings

Gilead Sciences 2Q EPS $1.56 >GILD

27 Apr 2025, 11:00 UTC

Top News

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 Apr 2025, 20:08 UTC

Earnings

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 Apr 2025, 20:02 UTC

Earnings

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 Apr 2025, 20:02 UTC

Earnings

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 Apr 2025, 20:02 UTC

Earnings

Gilead Sciences 1Q Rev $6.67B >GILD

24 Apr 2025, 20:02 UTC

Earnings

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

Peer Comparison

Price change

Gilead Sciences Inc. Forecast

Price Target

By TipRanks

11.11% upside

12 Months Forecast

Average 125.52 USD  11.11%

High 143 USD

Low 98 USD

Based on 23 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

23 ratings

18

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

97.33 / 103.17Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

44 / 371 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.